Best peptides, by goal.
Most “best peptide” lists rank by what sells. These rank by what has actually been published, using the same evidence tier as the rest of the site. Sometimes the honest answer for a goal is that nothing here is proven, and the page says so.
This is the one goal where the honest answer is genuinely impressive, and where the gap between the top of the list and everything else is the widest on the site.
A category with enormous marketing energy behind it and almost no completed human outcome evidence to show for it.
The most popular research peptide category, and the one where personal experience is least able to tell you whether anything worked.
A small category with an unusual feature: one of its compounds actually completed late-stage human trials, and the result was not what the field hoped.
The category with the largest claims, the longest timelines, and a measurement problem that no amount of enthusiasm resolves.
Low stakes, low regulatory bar, and an evidence base largely generated by the people selling the ingredients.
A category with real search demand, a memorable name at the centre of it, and a trial record that almost nobody quotes.
Where the outcomes are subjective, the placebo response is enormous, and the compound with the most trial evidence produced the least encouraging result.
A small category containing a genuinely approved drug and a widely-sold unapproved compound trading on its mechanism.
Real biology, persistent translation difficulty, and a reminder that modulating immunity in either direction has consequences.
A young field built on a real discovery, where the gap between the mitochondrial biology and the marketing is unusually wide.
High search demand, minimal clinical evidence, and a mechanism story doing most of the work.